{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:50:35Z","timestamp":1791402635889,"version":"4.3.3"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Side effects of immune checkpoint inhibitors (ICIs), called immune-related adverse events (irAEs), closely resemble primary autoimmune or rheumatic diseases. We aimed to understand the clinical utility of rheumatic autoantibodies (rhAbs) for diagnosing irAEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients without pre-existing autoimmune disease (pAID) who had cancer treated with ICI(s) treatment from 1\/1\/2011 to 12\/21\/2020 and a rhAb checked were retrospectively identified. Logistic regression assessed associations between autoantibodies and irAEs, cancer outcome, and survival. Specificity, sensitivity, and positive\/negative predictive values (PPV, NPV) were estimated for key rhAbs and ICI-arthritis. Kaplan-Meier analyzed objective response rate (ORR) and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2662 patients were treated with\u22651 ICIs. One hundred and thirty-five without pAID had\u2005\u2265\u20051 rhAb tested. Of which 70\/135(52%) were female; median age at cancer diagnosis was 62 years with most common cancers: melanoma (23%) or non\u2013small cell lung cancer (21%), 96\/135 (75%) were anti-PD1\/PDL1 treated. Eighty had a rhAb ordered before ICI, 96 after ICI, and 12 before and after. Eighty-two (61%) experienced an irAE, 33 (24%) with rheumatic-irAE. Pre-ICI RF showed significant association with rheumatic-irAEs (OR\u2005=\u200525, 95% CI, 1.52-410.86, P\u2005=\u2005.024). Pre\u2013 and post\u2013ICI RF yielded high specificity for ICI-arthritis (93% and 78%), as did pre\u2013 and post\u2013ICI CCP (100% and 91%). Pre\u2013ICI RF carried 93% NPV and pre\u2013ICI CCP had 89% PPV for ICI-arthritis. No variables were significantly correlated with ORR. Any-type irAE, rheumatic-irAE and ICI-arthritis were all associated with better OS (P\u2005=\u2005.000, P\u2005=\u2005.028, P\u2005=\u2005.019).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pre\u2013ICI RF was associated with higher odds of rheumatic-irAEs. IrAEs had better OS; therefore, clinical contextualization for rhAbs is critical to prevent unnecessary withholding of lifesaving ICI for fear of irAEs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac252","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T17:34:37Z","timestamp":1672767277000},"page":"440-448","source":"Crossref","is-referenced-by-count":20,"title":["Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events"],"prefix":"10.1093","volume":"28","author":[{"given":"Kristen","family":"Mathias","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Chicago Medical Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-847X","authenticated-orcid":false,"given":"Sherin","family":"Rouhani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology Oncology , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology Oncology , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-8351","authenticated-orcid":false,"given":"Anne R","family":"Bass","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5727-3972","authenticated-orcid":false,"given":"Thomas F","family":"Gajewski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology Oncology , Chicago, IL , USA"},{"name":"Committee on Clinical Pharmacology and Pharmacogenomics , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-0919","authenticated-orcid":false,"given":"Pankti","family":"Reid","sequence":"additional","affiliation":[{"name":"Committee on Clinical Pharmacology and Pharmacogenomics , Chicago, IL , USA"},{"name":"Department of Medicine, Section of Rheumatology, University of Chicago Medical Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"issue":"12","key":"2023050815251445900_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"9","key":"2023050815251445900_CIT0002","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11912-018-0718-6","article-title":"Immune Checkpoint Inhibitor Toxicity","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2023050815251445900_CIT0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2023050815251445900_CIT0004","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"issue":"230","key":"2023050815251445900_CIT0005","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"2","key":"2023050815251445900_CIT0006","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"2023050815251445900_CIT0007","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3389\/fimmu.2019.01934","article-title":"Checkpoint inhibition may trigger the rare variant of anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid","volume":"10","author":"Sadik","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2023050815251445900_CIT0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel","year":"2019","journal-title":"Cancer Immunol Res."},{"issue":"3","key":"2023050815251445900_CIT0009","first-page":"114","article-title":"Sicca\/Sjogren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol."},{"issue":"1","key":"2023050815251445900_CIT0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2023050815251445900_CIT0011","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"2023050815251445900_CIT0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"issue":"3","key":"2023050815251445900_CIT0013","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti\u2013PD-1 therapy for advanced non\u2013small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"issue":"44","key":"2023050815251445900_CIT0014","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2023050815251445900_CIT0015","doi-asserted-by":"crossref","first-page":"e004008","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J ImmunoTher Cancer"},{"issue":"1","key":"2023050815251445900_CIT0016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2023050815251445900_CIT0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"2023050815251445900_CIT0018","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023050815251445900_CIT0019","doi-asserted-by":"crossref","first-page":"585311","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events\u2014a comprehensive review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"2023050815251445900_CIT0020","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"2023050815251445900_CIT0021","doi-asserted-by":"crossref","first-page":"e002261","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J ImmunoTher Cancer"},{"issue":"11","key":"2023050815251445900_CIT0022","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer"},{"issue":"2","key":"2023050815251445900_CIT0023","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/CRST.CRST_88_19","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: a real-world experience from a tertiary cancer center.","volume":"2","author":"Kapoor","year":"2019","journal-title":"Cancer Res, Stat, Treatment"},{"issue":"18","key":"2023050815251445900_CIT0024","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"2023050815251445900_CIT0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"2023050815251445900_CIT0026","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/08916939009002982","article-title":"Autoantibodies in cancer patients: are they tumor related or age related?","volume":"5","author":"Huminer","year":"1990","journal-title":"Autoimmunity."},{"issue":"4","key":"2023050815251445900_CIT0027","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cancers13040591","article-title":"Rheumatoid factor: a novel determiner in cancer history","volume":"13","author":"Ugolini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2023050815251445900_CIT0028","first-page":"181","article-title":"Observations on non-specific Waaler-Rose and latex reactions in cancer patients","volume":"54","author":"Hurri","year":"1965","journal-title":"Ann Med Internae Fenniae"},{"issue":"6","key":"2023050815251445900_CIT0029","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1155\/2013\/726598","article-title":"Rheumatoid factors: clinical applications","volume":"35","author":"Ingegnoli","year":"2013","journal-title":"Dis Markers"},{"issue":"3","key":"2023050815251445900_CIT0030","first-page":"253","article-title":"[Antinuclear antibodies (ANA) in patients with malignant diseases: frequency of occurrence and immunological characterization (author\u2019s transl)]","volume":"167","author":"Idel","year":"1978","journal-title":"Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene Erste Abteilung Originale Reihe B: Hygiene, Betriebshygiene, praventive Medizin"},{"issue":"3","key":"2023050815251445900_CIT0031","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/0961203304lu521oa","article-title":"Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes","volume":"13","author":"Solans-Laqu\u00e9","year":"2004","journal-title":"Lupus."},{"issue":"7774","key":"2023050815251445900_CIT0032","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(72)91842-9","article-title":"Antinuclear antibodies in patients with malignancies","volume":"2","author":"Burnham","year":"1972","journal-title":"Lancet"},{"issue":"7785","key":"2023050815251445900_CIT0033","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(72)92453-1","article-title":"Malignancy associated with antinuclear antibodies","volume":"2","author":"Zeromski","year":"1972","journal-title":"Lancet"},{"issue":"4","key":"2023050815251445900_CIT0034","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert perspective: immune checkpoint inhibitors and rheumatologic complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"2023050815251445900_CIT0035","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia-Pacific J Clin Oncol."},{"key":"2023050815251445900_CIT0036","first-page":"1759720X21100691759720x","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Therapeut Adv Musculoskeletal Dis."},{"issue":"2","key":"2023050815251445900_CIT0037","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"2023050815251445900_CIT0038","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023050815251445900_CIT0039","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar551","article-title":"Autoantibodies in rheumatoid arthritis and their clinical significance","volume":"4","author":"Steiner","year":"2002","journal-title":"Arthritis Res"},{"issue":"3","key":"2023050815251445900_CIT0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2023050815251445900_CIT0041","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2023050815251445900_CIT0042","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41584-020-00522-w","article-title":"Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases","volume":"16","author":"Bossuyt","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"2023050815251445900_CIT0043","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/440\/50247578\/oyac252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/440\/50247578\/oyac252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:38:58Z","timestamp":1683563938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/440\/6967750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,3]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac252","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,1,3]]}}}